Telomir Completes TELI Acquisition, Secures Global Rights to Lead Drug Telomir-1, Receives $1M Funding
TELO sits 31% above its 52-week low of $1.05.
Summary
Telomir Pharmaceuticals has successfully completed its acquisition of TELI Pharmaceuticals, consolidating global rights to its lead therapeutic candidate, Telomir-1 (Telomir-Zn), under a single corporate structure. This strategic transaction includes an immediate $1.0 million in funding, with the potential for up to an additional $4.0 million in milestone-based contributions from former TELI shareholders. This follows the company's recent 10-K filing which highlighted financial challenges and a going concern warning, making the capital infusion and IP consolidation particularly significant. The acquisition also aligns with Telomir's recent Investigational New Drug (IND) submission for Telomir-Zn, positioning the company to advance into planned Phase 1/2 clinical trials. Investors will now monitor the FDA's IND clearance and the initiation of clinical trials, which are critical for both drug development and unlocking further milestone funding.
At the time of this announcement, TELO was trading at $1.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $47.4M. The 52-week trading range was $1.05 to $3.10. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Access Newswire.